Cullinan Therapeutics, Inc. — Form 8-K
Filed September 24, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Cullinan Therapeutics outlined three key clinical data presentations planned for Q4 2026: CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren's disease in December; velinotamig (BCMA TCE) multi-dose data in SLE at ACR Convergence on November 8, 2026; and CLN-049 (FLT3 TCE) updated Phase 1 data in AML in December. No financial terms, trial results, or regulatory outcomes are disclosed—only presentation schedules.
Why this rating
Clinical milestone announcements are routine; no data disclosed, financial impact, or material outcome. Positive/negative direction unknown until results presented.
See more from September 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.